hs-CRP Test – High-Sensitivity C-Reactive Protein

High-sensitivity C-reactive protein (hs-CRP) is a blood test that measures low levels of C-reactive protein, a marker of systemic inflammation, to help assess risk of cardiovascular disease and monitor chronic inflammatory conditions; clinicians use hs-CRP alongside lipid panels, blood pressure, and clinical history to stratify patients into low, intermediate, or high risk for heart attack and stroke, guide preventive strategies, and track response to lifestyle changes or therapy.

hs-CRP Results Interpretation & Risk Assessment

hs-CRP results are interpreted using standard risk bands—<1 mg/L indicates low cardiovascular risk, 1–3 mg/L intermediate risk, and >3 mg/L high risk—but values can be transiently elevated by acute infection or inflammation, so repeat testing and clinical correlation are essential; clinicians integrate hs-CRP with lipid panels, blood pressure, smoking status, diabetes, and family history to refine risk stratification, guide preventive therapies (statins, lifestyle changes), and monitor treatment response.

What is hs-CRP and How Does it Differ from Standard CRP?

High-sensitivity C-reactive protein (hs-CRP) is a more analytically sensitive form of the CRP blood test designed to detect low-grade systemic inflammation linked to cardiovascular risk, using assays that quantify CRP down to tenths of mg/L so clinicians can stratify heart attack and stroke risk (<1 mg/L low, 1–3 mg/L intermediate, >3 mg/L high); by contrast, standard CRP assays are calibrated for higher concentrations and are used to detect and monitor acute inflammation or infection (often reporting values in mg/dL), so while elevated standard CRP signals active inflammatory disease, hs-CRP is specifically useful for cardiovascular risk prediction and preventive management, with results interpreted in clinical context and repeated if acute illness may have transiently raised levels.

Normal hs-CRP Values & Risk Stratification

Normal hs-CRP values are used to stratify cardiovascular risk: <1 mg/L indicates low risk, 1–3 mg/L intermediate risk, and >3 mg/L high risk. Because hs-CRP detects low-grade systemic inflammation, clinicians interpret results in the context of lipid panels, blood pressure, smoking, diabetes, family history and recent illnesses (transient infections can raise CRP), repeat testing when indicated, and use the combined assessment to guide preventive measures such as lifestyle change and statin therapy.

Elevated hs-CRP: Inflammation & Chronic Disease

Elevated hs-CRP reflects low-grade systemic inflammation that is associated with higher risk of cardiovascular events and other chronic inflammatory conditions; values are interpreted using risk bands (<1 mg/L low, 1–3 mg/L intermediate, >3 mg/L high), but transient rises from acute infection or injury require repeat testing and clinical correlation—clinicians integrate hs-CRP with lipids, blood pressure, smoking, diabetes, and family history to refine risk stratification and guide preventive strategies such as lifestyle modification and statin therapy.

Low hs-CRP & Healthy Inflammation Status

Low hs-CRP (<1 mg/L) indicates low-grade systemic inflammation and is associated with lower cardiovascular risk; when combined with favorable lipid levels, normal blood pressure, non-smoking status, and no diabetes or strong family history, it supports a healthy inflammation profile and informs preventive care focused on maintaining lifestyle measures rather than initiating anti-inflammatory or statin therapy, while clinicians still consider repeat testing if recent infection or other transient factors could have suppressed or elevated values.

How to interpret your hs-CRP result in cardiovascular context

A single hs-CRP number is rarely the whole story. Because hs-CRP reflects low-grade systemic inflammation, the same value can mean different things depending on context. The American Heart Association strata anchor interpretation: below 1.0 mg/L corresponds to lower relative cardiovascular risk, 1.0 to 3.0 mg/L to average risk, and above 3.0 mg/L to higher risk.

Two findings shape how clinicians read the number. CRP rises with any inflammation — infection, injury, or active inflammatory disease can all push the level up, and the cause cannot always be determined from the number alone. Standard CRP measurements above 10 mg/dL are considered a marked increase reflecting active inflammation, which clinicians separate from chronic, low-grade cardiovascular signal.

Putting your number in context

The marker carries the most weight when other risk inputs are uncertain — when a 10-year ASCVD risk score sits in the borderline-to-intermediate range and preventive therapy could go either way. hs-CRP then adds prognostic information comparable to blood pressure or cholesterol, and global risk algorithms that include hs-CRP outperform those built only on Framingham covariates.

A practical workflow:

Combine the result with lipids, blood pressure, smoking status, diabetes, and family history rather than reading it as a standalone verdict.
Re-anchor to your ASCVD score — hs-CRP is most useful when statin decisions are uncertain, not when overall risk is already clearly low or clearly high.
Consider acute illness, recent infection, pregnancy, or oral contraceptive use as alternative explanations for an elevated number.

How hs-CRP fits into cardiovascular risk assessment alongside lipids and ASCVD score

Cholesterol screening misses many who later have heart attacks — only about 50% of heart attack patients have high LDL. Heart attacks are now understood as an inflammatory process as much as a plumbing problem: LDL particles injure the arterial wall, immune cells move in, foam cells accumulate, and a fibrous cap eventually ruptures and triggers a clot.

Where hs-CRP slots into the risk panel

Cleveland Clinic groups hs-CRP with roughly a dozen markers used to stratify coronary artery disease risk, including LDL and the rest of the lipid panel, Lp(a), ApoB, homocysteine, fibrinogen, NT-proBNP, and the ASCVD risk score itself. The ASCVD score uses bands of below 5% (low), 5 to 7.5% (borderline), greater than 7.5% to below 20% (intermediate), and above 20% (high) ten-year risk.

One published analysis found the high-CRP / low-LDL group carried greater cardiovascular risk than the low-CRP / high-LDL group, and the two tests identified different high-risk populations — a normal cholesterol panel does not by itself rule out inflammation-driven risk.

What this means for borderline patients

U.S. guidelines assign hs-CRP a class IIb recommendation and describe it as “most appropriate in primary prevention when clinical decisions to initiate statin therapy are uncertain”. In practice, that translates to a tie-breaker for someone with intermediate ASCVD risk, normal-to-borderline LDL, and a family history of premature coronary disease. The decision belongs to the clinician and patient — hs-CRP supplies one more data point, not a verdict.

Lifestyle and clinical factors that raise hs-CRP and what lowers it

Behaviors that drive cardiovascular risk also drive the hs-CRP number.

Factors that tend to raise hs-CRP

Infection and active inflammatory disease — CRP rises with any inflammation, and infection is a named cause.
Pregnancy and oral contraceptives — positive CRP results occur during the last half of pregnancy and with the use of birth control pills.
Other inflammatory conditions — cancer, heart attack, inflammatory bowel disease, rheumatoid arthritis, lupus, and rheumatic fever are all named causes, although hs-CRP is not the test used to manage them.

Behavioral drivers of cardiovascular risk — smoking, excess weight, inactivity — are the targets of first-line response. U.S. guideline framing names diet, exercise, and smoking cessation as the first steps for patients with a proinflammatory response.

Interventions documented to lower hs-CRP

Exercise is described as “a great way to bring down your CRP level”.
Weight loss also lowers CRP.
Smoking cessation is listed alongside diet and exercise as a first-line step.
Statins lower CRP as well as LDL.

Trial evidence comes from JUPITER. Statins reduced the rate of first myocardial infarction, stroke, or confirmed cardiovascular death by 47% in patients with LDL-C below 130 mg/dL and hs-CRP above 2 mg/L (hazard ratio 0.53; 95% CI 0.40 to 0.69; p less than 0.00001). The trial identified a population whose risk was driven by inflammation rather than cholesterol — a group conventional LDL-based screening would have missed. Whether a statin is appropriate for any individual is a clinician decision.

How to prepare for an hs-CRP test and what to expect

No special steps are needed to prepare for a CRP or hs-CRP blood draw. The test uses a standard venous blood sample drawn from a vein in the arm via routine venipuncture. Most people feel a brief prick or sting; minor risks include excessive bleeding, fainting or light-headedness, hematoma, and a small risk of infection at the draw site.

Timing considerations

Because hs-CRP responds to inflammation, what is happening in your body around the draw matters:

Any active infection, injury, or inflammatory flare can raise CRP and complicate interpretation.
Pregnancy in the second half of gestation and oral contraceptive use also raise CRP.

If you have been acutely unwell, ask whether to defer the test so the result reflects chronic inflammation rather than passing illness.

Turnaround and results delivery

Lab turnaround is typically a few days or longer; call back if you have not received results within a couple of weeks. Results are reported in mg/L for hs-CRP assays, which are sensitive enough to measure CRP at 1 mg/L or below — the resolution needed for cardiovascular risk stratification.

Tracking hs-CRP over time: monitoring response to therapy

A single hs-CRP measurement is a snapshot, and the marker becomes more informative when tracked across time. When exercise, weight loss, smoking cessation, or statin therapy are started, the interventions documented to lower CRP can shift the trajectory.

Trending hs-CRP serves two purposes. First, it offers a window onto biological response: a number that is not moving after sustained intervention prompts a conversation about adherence and other contributors to inflammation. Second, it can re-anchor risk discussion if the value crosses from the higher-risk band into the average or lower band.

What the trend cannot do

The JUPITER outcome benefit — a 47% reduction in first MI, stroke, or confirmed cardiovascular death — was observed in a defined population selected on LDL-C below 130 mg/dL and hs-CRP above 2 mg/L. That is a population-level result, not a target-to-treat number for individuals. A transient infection or inflammatory flare around the time of a draw can also mimic a worsening trend.

Limitations of hs-CRP and when it should not be used

hs-CRP is informative, but not a universal screening tool. Several specific situations limit what it can tell you.

Where the test is most and least useful

Most useful: in primary prevention when statin decisions are uncertain — the situation flagged by U.S. guidelines, which assign hs-CRP a class IIb recommendation.
Least useful: when overall cardiovascular risk is already clearly low or clearly high; hs-CRP rarely changes management in those cases.

Conditions and states that limit interpretation

Active inflammation or infection — an elevated reading during illness reflects the acute process rather than chronic cardiovascular signal.
Rheumatoid arthritis and lupus — CRP levels may not rise in some people with these conditions, and the reason is unknown. A normal hs-CRP in someone with established autoimmune disease should not be read as evidence against inflammation.
Pregnancy and oral contraceptives — both raise CRP and complicate interpretation.
Standard CRP elevations above 10 mg/dL — categorized as a marked increase tied to active inflammatory disease, not the chronic low-grade signal hs-CRP was designed to capture.

hs-CRP is also not a diagnostic test for heart disease. A high value does not mean a heart attack is imminent, and a low value does not guarantee a healthy cardiovascular future. It is not the same as the standard CRP test, used to detect and monitor active inflammatory disease.

Frequently asked questions

What is hs-CRP and how is it different from a regular CRP test?

Both measure C-reactive protein, a liver-produced acute-phase protein that rises with inflammation. The high-sensitivity assay is calibrated to detect very low concentrations — 1 mg/L or below — the range that matters for cardiovascular risk stratification. Standard CRP is used to check for inflammation and monitor diseases such as rheumatoid arthritis or lupus.

What does it mean if my hs-CRP is high?

A higher value reflects more systemic inflammation and higher relative cardiovascular risk: above 3.0 mg/L places the result in the high-risk band per American Heart Association criteria. The cause cannot always be determined from the number alone, and any inflammation — including infection — can push it up.

Do I need to fast before an hs-CRP test?

No. No special steps are needed to prepare for an hs-CRP blood draw. If hs-CRP is ordered alongside a lipid panel, your clinician may still ask you to fast for the cholesterol portion.

What is the normal range for hs-CRP?

The American Heart Association strata are: below 1.0 mg/L for lower cardiovascular risk, 1.0 to 3.0 mg/L for average risk, and above 3.0 mg/L for higher risk. Cleveland Clinic notes that local laboratory cutoffs can differ, so results should be discussed in the context of the lab that ran them.

What infections or illnesses can cause a high hs-CRP?

Any inflammation can elevate CRP, and the cause cannot always be pinpointed from the number alone. Infection, cancer, heart attack, inflammatory bowel disease, rheumatoid arthritis, lupus, and rheumatic fever are all named causes; pregnancy in the second half of gestation and oral contraceptive use also raise CRP.

If my hs-CRP is high but my cholesterol is normal, am I still at risk?

Possibly yes. One published analysis found people with high CRP and low LDL had greater cardiovascular risk than people with low CRP and high LDL, and the two tests identified different high-risk groups. A normal lipid panel does not by itself rule out inflammation-driven cardiovascular risk.

Can lifestyle changes lower hs-CRP?

Yes. Diet, exercise, and smoking cessation are the first steps for a proinflammatory response per U.S. guideline framing. Harvard specifies that exercise is a great way to lower CRP and that weight loss also works. Statins, when prescribed, lower CRP alongside LDL.

When to talk to your doctor about your hs-CRP results

Talk to your clinician about your hs-CRP result in any of these specific situations:

Your hs-CRP places you above 3.0 mg/L — the higher relative cardiovascular risk band per American Heart Association criteria, which warrants discussion of preventive strategies.
Your standard CRP is above 10 mg/dL — a marked increase that signals active inflammatory disease rather than chronic cardiovascular risk, warranting evaluation of what is driving it.
Your hs-CRP is elevated and you have chest pain, exertional shortness of breath, or other cardiovascular symptoms — symptoms always take precedence over a single laboratory value.
Your hs-CRP is elevated, your LDL is normal, and you have a family history of premature coronary disease — the high-CRP / low-LDL pattern that conventional cholesterol screening can miss.
You are tracking response to lifestyle changes or statin therapy and your hs-CRP has not moved — a reason to revisit adherence and other contributors to inflammation.
You have an established autoimmune diagnosis such as rheumatoid arthritis or lupus and your hs-CRP is normal — CRP may not rise predictably in these conditions.
You are pregnant, recently postpartum, or using oral contraceptives and have an unexpectedly elevated hs-CRP — these states raise CRP independently of cardiovascular risk.

The decision about preventive therapy belongs to your clinician, who weighs hs-CRP alongside lipids, blood pressure, family history, and your full clinical picture.

References

Last reviewed: 2026-05-12